Guangzhou Green Cross Pharmaceuticals was established in 1991 as a comprehensive pharmaceutical enterprise specializing in the research, production, and sales of high-end parenteral nutrition formulations and a diverse range of chemical drugs. The company has built a closed-loop, fully integrated industrial chain, equipped with complete production, R&D, and sales systems. It owns a wholly-owned R&D subsidiary, Saifeng Pharmaceuticals, a majority-owned production subsidiary, Huineng Pharmaceuticals, and a wholly-owned sales subsidiary, Kemao Pharmaceuticals. In 2021, the company established Shandong Haoruien and Guangdong Haoruien to create two major formulation production bases in Shandong and Guangdong. In 2023, Shandong Ruien Biotech was founded as the group's active pharmaceutical ingredient (API) production base.
The company places a strong emphasis on attracting high-end pharmaceutical talent and upgrading its product portfolio. Evolving from a leading amino acid producer to a comprehensive chemical pharmaceutical enterprise specializing in high-value APIs, innovative drugs, and high-end generics, it strives to become one of the most respected pharmaceutical companies.
